Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.
The University of Maryland School of Medicine is launching a $500 million fundraising campaign, the largest in the school’s history.
The school plans to officially launch the capital campaign, “Transforming Medicine Beyond Imagination,” at its annual gala May 11. The event is considered a critical fundraiser for the school’s research and clinical programs.
May 15, 2013 8:00am – 10:00am
Tower Club, Tysons Corner
Attracting and retaining key employees is a challenge every business faces, and government contractors know that a valuable contract can hinge on making the right staffing choices. Savvy government contractors also recognize the necessity to maximize human capital within the constraints of sequestration, continuing resolution and lowest price technically acceptable contracts.
You’re invited to this breakfast workshop to learn about powerful employee incentive compensation strategies that can provide significant competitive advantages for your business. These often underutilized plans can attract top quality employees through cash, equity and other equity-linked compensation methods. In addition to creating great work environments, innovative incentive plans allow government contractors to be successful amidst the current era of regulatory challenges.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license agreement with United Therapeutics Corporation (Nasdaq:UTHR) for the use of Pluristem’s PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH).
Under the terms of the agreement, United Therapeutics will receive exclusive worldwide licensing rights for the development and commercialization of the future product for treating PH patients. Pluristem will retain all manufacturing rights; participate in the pre-clinical and clinical trial activities, as well as provide the commercial grade product.
UK pharmaceuticals giant GlaxoSmithKline has unveiled an “open innovation” platform through which it will publish data from its clinical trials online so it can be analysed by external researchers.
The online system allows scientists to submit a to request access anonymised drug trial data. Each request will be judged a panel of external experts appointed by GSK, and applicants must agree to publish their own findings.
A Johns Hopkins University faculty member will be helping advise the National Institutes of Health about research topics with the most promise for addressing public health challenges.
Janice E. Clements, vice dean for faculty at the Johns Hopkins University School of Medicine, has been selected to serve on the Council of Councils for NIH. Clements was among 10 individuals newly selected to serve on the 27-member council. Her term ends in October 2015.